Article Text

PDF
J9 Probing huntington’s disease phenocopy syndromes with next-generation sequencing
  1. Carolin Koriath1,
  2. Gary Adamson2,
  3. Ronald Druyeh2,
  4. Janna Kenny2,
  5. John Collinge2,
  6. Edward Wild1,
  7. Henry Houlden3,
  8. Mark Gaskin3,
  9. Simon Mead2,
  10. Sarah Tabrizi1
  1. 1Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
  2. 2MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
  3. 3Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

Abstract

Background and aims Huntington’s disease (HD) is an autosomal-dominant condition and defined by a triad of movement, cognitive, and psychiatric symptoms. However, some patients in whom HD is suspected do not carry the CAG expansion in the Huntingtin gene (HTT). These cases, with symptoms on the HD spectrum, but without the HTT expansion, are called HD phenocopy syndromes. Their most frequent known cause has recently been identified as C9orf72, but recessive conditions can also mimic HD. Next generation sequencing technologies (NGS) facilitate the simultaneously screening of genes linked to other neurodegenerative conditions.

Methods We applied a validated 17-gene NGS dementia panel (PRNP, PSEN1, PSEN2, APP, GRN, MAPT, TREM2, CHMP2B, CSF1R, FUS, ITM2B, NOTCH3, SERPINI1, SQSTM1, TARDBP, TYROBP and VCP) combined with PCR-based assessments of the C9orf72 and PRNP expansions to the UCL HD phenocopy cohort (n = 444). We classified mutations by likelihood of pathogenicity and compared with clinical data, including HD-likeness and family history.

Results In the cohort, 7.2% of all patients displayed the complete triad of symptoms, and for 46.9% of these a relevant family history was reported. A further 32.7% presented with 2/3 of the triad, 20.3% of these had a relevant family history. Overall, a relevant family history was reported for 24% of patients. In the 409 cases processed so far, yet to be tested for the C9orf72 and PRNP expansions, 4.5% of patients were found to carry a (likely) deleterious variant, a further 4.1% carried a potentially deleterious variant and 7.9% carried a higher-risk allele.

Conclusions A custom panel provides affordable high quality sequencing. These panels can now help identify mutations in genes not previously linked to HD phenocopies, and reduce the number of cases where even with a strong family history no genetic mutation is found. This ongoing work will help to provide answers to patients and families, who present with an HD syndrome without the diagnostic certainty of the HTT expansion.

  • HD phenocopy syndromes
  • HD-like
  • next-generation sequencing

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.